Cholesterol-lowering drug taken off market

A halt in the marketing of Tredaptive, a cholesterol-lowering drug made by MSD, is announced by the Health Ministry.

By
January 14, 2013 22:07
1 minute read.
Various pills [illustrative photo]

Pills medicine medication treatment 370 (R). (photo credit: Srdjan Zivulovic / Reuters)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

A halt in the marketing of Tredaptive, a cholesterol-lowering drug made by MSD, was announced by the Health Ministry on Monday.

The company decided to stop selling the dyslipidemia medication after a research project called HPS-2-THRIVE showed the drug posed risks and the CE European drug certification authority recommended that it no longer be used.

Preliminary findings “did not show that taking the drug reduces the prevalence of significant heart attacks and strokes; at the same time, it did show an increase in side effects to the circulatory and lymph systems, the digestive system, infections, metabolism, the skeletal and muscular systems, the respiratory system and the skin among those taking the prescription medication,” the ministry stated.


The ministry’s pharmaceutical division advised patients taking the drug to consult with their doctors to consider an alternate therapy. The ministry stressed, however, that patients should not stop taking Tredaptive without being advised to do so by their physician.

MSD said on December 27 that doctors should not give the drug for the first time to patients and that they should consider whether to continue prescribing it to patients as a result of the research. The ministry said the decision “does not result from getting new safety information beyond MSD’s announcement in December but is the result of regulatory activity.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Lab
August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice

By JUDY SIEGEL-ITZKOVICH